BUZZ - Aquestive shares surge after reaching US licensing agreement with Eton Pharma for anti-epileptic drug

October 14 - ** Aquestive Therapeutics (AQST.O) shares rose 4.3% in pre-market trading to $4.87

** The pharmaceutical company said it has (link) granted exclusive U.S. rights to its Libervant medication to Eton Pharmaceuticals ETON.O

** The anti-epileptic drug is expected to launch in April 2027, subject to final approval

** Libervant is a dissolvable diazepam film placed inside the cheek, designed for patients with intermittent seizures; it can be used as an alternative to nasal sprays and rectal administration forms

** The medication was approved by the FDA in April for patients aged 2 to 5 years

** The FDA is reviewing an application to expand usage to children aged 6 to 11; a decision is expected before April

** Shares have fallen 27% so far this year

(To facilitate non-native English speakers, Reuters provides automated translation of its reports in several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers' convenience. Reuters accepts no liability for any damage or loss caused by use of the automated translation feature.)